These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 1739628)

  • 1. A phase I study on the reversal of multidrug resistance (MDR) in vivo: nifedipine plus etoposide.
    Philip PA; Joel S; Monkman SC; Dolega-Ossowski E; Tonkin K; Carmichael J; Idle JR; Harris AL
    Br J Cancer; 1992 Feb; 65(2):267-70. PubMed ID: 1739628
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I and pharmacological study of sequential intravenous topotecan and oral etoposide.
    Herben VM; ten Bokkel Huinink WW; Dubbelman AC; Mandjes IA; Groot Y; van Gortel-van Zomeren DM; Beijnen JH
    Br J Cancer; 1997; 76(11):1500-8. PubMed ID: 9400949
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Etoposide bioavailability after oral administration of the prodrug etoposide phosphate in cancer patients during a phase I study.
    Chabot GG; Armand JP; Terret C; de Forni M; Abigerges D; Winograd B; Igwemezie L; Schacter L; Kaul S; Ropers J; Bonnay M
    J Clin Oncol; 1996 Jul; 14(7):2020-30. PubMed ID: 8683232
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance.
    Lum BL; Kaubisch S; Yahanda AM; Adler KM; Jew L; Ehsan MN; Brophy NA; Halsey J; Gosland MP; Sikic BI
    J Clin Oncol; 1992 Oct; 10(10):1635-42. PubMed ID: 1403041
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I and pharmacologic study of the MDR converter GF120918 in combination with doxorubicin in patients with advanced solid tumors.
    Planting AS; Sonneveld P; van der Gaast A; Sparreboom A; van der Burg ME; Luyten GP; de Leeuw K; de Boer-Dennert M; Wissel PS; Jewell RC; Paul EM; Purvis NB; Verweij J
    Cancer Chemother Pharmacol; 2005 Jan; 55(1):91-9. PubMed ID: 15565444
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I and pharmacokinetic study of paclitaxel in combination with biricodar, a novel agent that reverses multidrug resistance conferred by overexpression of both MDR1 and MRP.
    Rowinsky EK; Smith L; Wang YM; Chaturvedi P; Villalona M; Campbell E; Aylesworth C; Eckhardt SG; Hammond L; Kraynak M; Drengler R; Stephenson J; Harding MW; Von Hoff DD
    J Clin Oncol; 1998 Sep; 16(9):2964-76. PubMed ID: 9738565
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I study of high-dose etoposide phosphate in man.
    Fields SZ; Budman DR; Young RR; Kreis W; Ingram R; Schulman P; Cherny RC; Wright J; Behr J; Snow C; Schacter LP
    Bone Marrow Transplant; 1996 Nov; 18(5):851-6. PubMed ID: 8932836
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modulation of cytostatic drugs by nifedipine in two heterotransplanted human testicular-cancer cell lines differing in their sensitivity to standard agents.
    Bokemeyer C; Dunn T; Harstrick A; Lerch T; Poliwoda H; Schmoll HJ
    Int J Cancer; 1994 Feb; 56(3):452-6. PubMed ID: 7906255
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I study of etoposide phosphate administered as a daily 30-minute infusion for 5 days.
    Thompson DS; Greco A; Miller AA; Srinivas NR; Igwenezue KB; Hainsworth JD; Schacter LP; Kaul S; Barbhaiya RH; Garrow C
    Clin Pharmacol Ther; 1995 May; 57(5):499-507. PubMed ID: 7768072
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of 5-fluorouracil pharmacokinetics in patients receiving continuous 5-fluorouracil infusion and oral uracil plus N1-(2'-tetrahydrofuryl)-5-fluorouracil.
    Ho DH; Pazdur R; Covington W; Brown N; Huo YY; Lassere Y; Kuritani J
    Clin Cancer Res; 1998 Sep; 4(9):2085-8. PubMed ID: 9748123
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of high-dose cyclosporine on etoposide pharmacodynamics in a trial to reverse P-glycoprotein (MDR1 gene) mediated drug resistance.
    Lum BL; Kaubisch S; Fisher GA; Brown BW; Sikic BI
    Cancer Chemother Pharmacol; 2000; 45(4):305-11. PubMed ID: 10755319
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Continuous-infusion verapamil with etoposide in relapsed or resistant paediatric cancers.
    Cowie FJ; Pinkerton CR; Phillips M; Dick G; Judson I; McCarthy PT; Flanagan RJ
    Br J Cancer; 1995 Apr; 71(4):877-81. PubMed ID: 7710958
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I study of etoposide phosphate (etopophos) as a 30-minute infusion on days 1, 3, and 5.
    Fields SZ; Igwemezie LN; Kaul S; Schacter LP; Schilder RJ; Litam PP; Himpler BS; McAleer C; Wright J; Barbhaiya RH
    Clin Cancer Res; 1995 Jan; 1(1):105-11. PubMed ID: 9815892
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bioavailability, pharmacokinetics, and clinical effects of an oral preparation of etoposide.
    Stewart DJ; Nundy D; Maroun JA; Tetreault L; Prior J
    Cancer Treat Rep; 1985 Mar; 69(3):269-73. PubMed ID: 3884152
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Phase I-II study of sequential administration of topotecan and oral etoposide (toposiomerase I and II inhibitors) in the treatment of patients with small cell lung carcinoma.
    Mok TS; Wong H; Zee B; Yu KH; Leung TW; Lee TW; Yim A; Chan AT; Yeo W; Chak K; Johnson P
    Cancer; 2002 Oct; 95(7):1511-9. PubMed ID: 12237920
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rosiglitazone has no clinically significant effect on nifedipine pharmacokinetics.
    Harris RZ; Inglis AM; Miller AK; Thompson KA; Finnerty D; Patterson S; Jorkasky DK; Freed MI
    J Clin Pharmacol; 1999 Nov; 39(11):1189-94. PubMed ID: 10579151
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I study and clinical pharmacological evaluation of daily oral etoposide combined with carboplatin in patients with lung cancer.
    Ohune T; Fujiwara Y; Sumiyoshi H; Yamaoka N; Yamakido M
    Jpn J Cancer Res; 1995 May; 86(5):490-500. PubMed ID: 7790322
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I and pharmacokinetic study of etoposide phosphate by protracted venous infusion in patients with advanced cancer.
    Soni N; Meropol NJ; Pendyala L; Noel D; Schacter LP; Gunton KE; Creaven PJ
    J Clin Oncol; 1997 Feb; 15(2):766-72. PubMed ID: 9053503
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I clinical and pharmacokinetic study of S9788, a new multidrug-resistance reversal agent given alone and in combination with doxorubicin to patients with advanced solid tumors.
    Tranchand B; Catimel G; Lucas C; Sarkany M; Bastian G; Evene E; Guastalla JP; Négrier S; Rebattu P; Dumortier A; Foy M; Grossin F; Mazier B; Froudarakis M; Barbet N; Clavel M; Ardiet C
    Cancer Chemother Pharmacol; 1998; 41(4):281-91. PubMed ID: 9488597
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and bioequivalence of etoposide following intravenous administration of etoposide phosphate and etoposide in patients with solid tumors.
    Kaul S; Igwemezie LN; Stewart DJ; Fields SZ; Kosty M; Levithan N; Bukowski R; Gandara D; Goss G; O'Dwyer P
    J Clin Oncol; 1995 Nov; 13(11):2835-41. PubMed ID: 7595746
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.